HKSE - Delayed Quote HKD
TIANDA PHARMA (0455.HK)
0.155
+0.012
+(8.39%)
At close: 1:51:52 PM GMT+8
Breakdown
TTM
12/31/2024
12/31/2023
3/31/2022
3/31/2021
Total Revenue
329,937
329,937
532,089
509,955
474,332.111
Cost of Revenue
177,913
177,913
276,557
268,732
215,344.576
Gross Profit
152,024
152,024
255,532
241,223
258,987.535
Operating Expense
202,081
202,081
279,941
283,251
290,196.467
Operating Income
-50,057
-50,057
-24,409
-42,028
-31,208.932
Net Non Operating Interest Income Expense
-3,754
-3,754
-1,914
2,246
3,925.950
Pretax Income
-54,340
-54,340
-25,694
-28,018
-27,441.560
Tax Provision
7,074
7,074
-689
-6,343
-1,523.754
Net Income Common Stockholders
-61,371
-61,371
-24,155
-19,771
-27,142.070
Diluted NI Available to Com Stockholders
-61,371
-61,371
-24,155
-19,771
-27,142.070
Basic EPS
-0.03
--
-0.01
-0.01
-0.01
Diluted EPS
-0.03
--
-0.01
-0.01
-0.01
Basic Average Shares
2,150,041.884
--
2,150,041.884
2,150,041.884
2,150,041.884
Diluted Average Shares
2,150,041.884
--
2,150,041.884
2,150,041.884
2,150,041.884
Total Expenses
379,994
379,994
556,498
551,983
505,541.043
Net Income from Continuing & Discontinued Operation
-61,371
-61,371
-24,155
-19,771
-27,142.070
Normalized Income
-59,359.825
-59,359.825
-24,010.969
-26,015.270
-27,040.102
Interest Income
1,100
1,100
3,032
2,971
4,495.301
Interest Expense
4,854
4,854
4,946
725
569.351
Net Interest Income
-3,754
-3,754
-1,914
2,246
3,925.950
EBIT
-49,486
-49,486
-20,748
-27,293
-26,872.209
EBITDA
-11,254
-11,254
15,659
-5,144
-6,254.344
Reconciled Cost of Revenue
177,913
177,913
276,557
268,732
215,344.576
Reconciled Depreciation
38,232
38,232
36,407
22,149
20,617.865
Net Income from Continuing Operation Net Minority Interest
-61,371
-61,371
-24,155
-19,771
-27,142.070
Total Unusual Items Excluding Goodwill
-805
-805
-148
10,105
-107.903
Total Unusual Items
534
534
-148
11,682
-107.903
Normalized EBITDA
-11,788
-11,788
15,807
-16,826
-6,146.441
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-132.825
-132.825
-3.969
2,283.730
-5.935
3/31/2021 - 1/4/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade